The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...
A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...
Cases of severe RSV in two Moderna vaccine candidates' trials raise questions about future
Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children ...
Along with holiday arrangements, changing seasons signal the need for another type of preparation: vaccination.
The forthcoming RSV shot, expected to get US regulatory approval this month, is Moderna’s first chance to show the ...
Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.
Moderna is looking to make a swift dash to the finish line with its respiratory syncytial virus (RSV) vaccine candidate, based on the same mRNA technology as its COVID-19 shots, with a filing in ...
MinterEllison has advised Moderna in relation to its new mRNA manufacturing facility – a facility described by the firm as ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.DyCR3BqR.js ...
Moderna's shot was approved in the United States ... to make up for waning post-pandemic demand for COVID products. RSV, which typically causes cold-like symptoms, is a leading cause of pneumonia ...
Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback